Janux Therapeutics, Inc. (JANX) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Janux Therapeutics reported revenue of $10.0M, down 5.6% from $10.6M the year before. Net income was -$113.6M (a -1136.2% net margin), or -$1.83 per diluted share. Operating margin was -1576.7%. Operating activities generated -$82.2M of cash, leaving -$83.3M of free cash flow. At fiscal year end, Janux Therapeutics held $1.00B in total assets against $44.7M in total liabilities, including $52.3M of cash and equivalents.
Open the full interactive Janux Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Janux Therapeutics Key Stats
| Share Price | $17.18 |
|---|---|
| Market Cap | $1.08B |
| Revenue YoY Growth | -5.5% |
| 52-Week Range | $12.18 – $34.74 |
| Shares Outstanding | 62.9 million (basic, 2026 Q2) |
Janux Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $3.6M | $8.6M | $8.1M | $10.6M | $10.0M |
| Operating Income | -$32.9M | -$67.1M | -$73.0M | -$98.8M | -$157.7M |
| Pre-Tax Income | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| Income Tax | — | — | — | — | $0 |
| Net Income | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$113.6M |
| Diluted EPS | -$1.39 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
Janux Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $10.0M | $0 | $3.7M | $10.3M |
| Net Income | -$24.3M | -$31.9M | -$24.4M | -$22.0M |
| Diluted EPS | -$0.39 | -$0.52 | -$0.39 | -$0.35 |
Janux Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | $35.6M | $51.4M | $19.2M | $430.6M | $52.3M |
| Current Assets | $377.0M | $332.4M | $349.2M | $1.03B | $975.9M |
| Total Assets | $379.8M | $364.0M | $380.4M | $1.06B | $1.00B |
| Current Liabilities | $12.8M | $16.5M | $13.0M | $17.5M | $25.0M |
| Total Liabilities | $13.5M | $43.3M | $36.1M | $38.7M | $44.7M |
| Shareholders' Equity | $366.3M | $320.7M | $344.3M | $1.02B | $956.8M |
Janux Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$17.0M | -$42.9M | -$50.6M | -$43.8M | -$82.2M |
| Cash From Investing | -$341.0M | $58.3M | -$41.2M | -$258.0M | -$301.0M |
| Cash From Financing | $386.5M | $500,000 | $59.5M | $713.2M | $4.9M |
| Free Cash Flow | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
Figures from Janux Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Janux Therapeutics financials page for every line item.
Janux Therapeutics Company Profile
| Ticker | JANX |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | San Diego, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001817713 |
Frequently Asked Questions
What was Janux Therapeutics' revenue in fiscal 2025?
Janux Therapeutics (JANX) reported revenue of $10.0M for fiscal 2025.
What is Janux Therapeutics' annual revenue history?
Janux Therapeutics' annual revenue by fiscal year: 2021: $3.6M; 2022: $8.6M; 2023: $8.1M; 2024: $10.6M; 2025: $10.0M.
What was Janux Therapeutics' net income in fiscal 2025?
Janux Therapeutics reported net income of -$113.6M for fiscal 2025.
What was Janux Therapeutics' earnings per share (EPS) in fiscal 2025?
Janux Therapeutics' diluted EPS was -$1.83 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Janux Therapeutics generate in fiscal 2025?
Janux Therapeutics generated -$83.3M of free cash flow in fiscal 2025.
What was Janux Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Janux Therapeutics reported revenue of $10.3M.
How many shares of Janux Therapeutics are outstanding?
Janux Therapeutics reported a weighted average of 62.9 million basic shares outstanding in 2026 Q2.
What is Janux Therapeutics' market cap?
Based on its latest closing price, Janux Therapeutics (JANX) has a market capitalization of about $1.08B.
When does Janux Therapeutics' fiscal year end?
Janux Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Janux Therapeutics headquartered?
Janux Therapeutics lists its business address in San Diego, California in its SEC filings.